Jnana Therapeutics Presents New Positive Data from Phase 1/2 Study of JNT-517 in Individuals with Phenylketonuria – Results Support Planned Pivotal Study in Early 2025
04 sept. 2024 07h30 HE
|
Jnana Therapeutics, Inc.
Jnana Therapeutics presents new positive data at SSIEM 2024 from Phase 1/2 study of JNT-517 in individuals with phenylketonuria (PKU).
Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved with JNT-517, a Potential First-in-Class Oral Treatment for PKU
30 janv. 2024 08h15 HE
|
Jnana Therapeutics, Inc.
Jnana Therapeutics announces positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with PKU.
Synlogic Provides Corporate Update and Outlook for 2024
04 janv. 2024 07h00 HE
|
Synlogic, Inc.
- Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age - - Top-line, Phase 3 data in PKU expected in H1...
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
09 nov. 2023 07h00 HE
|
Synlogic, Inc.
- Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 - - Progress of the Synpheny-3 pivotal trial...
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
03 oct. 2023 16h15 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
29 sept. 2023 07h00 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism
28 sept. 2023 11h15 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic to Participate in Chardan’s Genetic Medicines Conference
21 sept. 2023 07h00 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100
19 sept. 2023 11h00 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Jnana Therapeutics Presents Additional Data from Phase 1a Clinical Study of JNT-517 at SSIEM Annual Symposium
31 août 2023 07h00 HE
|
Jnana Therapeutics, Inc.
JNT-517 demonstrated sustained, dose-dependent pharmacodynamic effects and was safe and well tolerated in healthy volunteers Phase 1b study is ongoing in individuals with PKU BOSTON, Aug. 31, 2023 ...